{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:08:35Z","timestamp":1792505315234,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.intimp.2014.04.006","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T17:45:51Z","timestamp":1397843151000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis"],"prefix":"10.1016","volume":"21","author":[{"given":"Seung Min","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Rim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ki","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Su","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyeon","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2014.04.006_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2014.04.006_bb0010","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012","volume":"72","author":"Furst","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2014.04.006_bb0020","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2014.04.006_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.intimp.2014.04.006_bb0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","article-title":"Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation","volume":"72","author":"van Schouwenburg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.2006.057406","article-title":"Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis","volume":"66","author":"van der Laken","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0040","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases","volume":"38","author":"Emi Aikawa","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2014.04.006_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jbspin.2009.11.015","article-title":"Clinical spectrum of ankylosing spondylitis in Korea","volume":"77","author":"Kim","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2014.04.006_bb0055","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00296-012-2590-2","article-title":"Prevalence and incidence of rheumatoid arthritis in South Korea","volume":"33","author":"Sung","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.intimp.2014.04.006_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11926-005-0002-2","article-title":"Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors","volume":"7","author":"Anderson","year":"2005","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.intimp.2014.04.006_bb0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2014.04.006_bb0070","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00296-006-0183-7","article-title":"Immunogenicity, efficacy and adverse events of adalimumab in RA patients","volume":"27","author":"Bender","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.intimp.2014.04.006_bb0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.04.006_bb0090","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0095","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","article-title":"Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab","volume":"71","author":"Plasencia","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0100","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.intimp.2014.04.006_bb0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ard.2010.136283","article-title":"Fc\u03b3 receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis","volume":"70","author":"Okuyama","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.006_bb0110","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/art.24709","article-title":"Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms","volume":"60","author":"Bartelds","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.04.006_bb0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1208\/s12248-009-9091-6","article-title":"Antidrug antibody assay validation: industry survey results","volume":"11","author":"Gorovits","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.intimp.2014.04.006_bb0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jim.2011.07.019","article-title":"Differential effect of drug interference in immunogenicity assays","volume":"372","author":"Hart","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.intimp.2014.04.006_bb0125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","article-title":"Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement","volume":"20","author":"Aarden","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.intimp.2014.04.006_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2010.03.012","article-title":"Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics","volume":"357","author":"Tatarewicz","year":"2010","journal-title":"J Immunol Methods"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914001301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914001301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T20:53:30Z","timestamp":1538686410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576914001301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1567576914001301"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2014.04.006","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2014.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}